A Study to Learn About The Study Medicine (Called PF-06823859) in Healthy Chinese Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2022

Primary Completion Date

March 21, 2023

Study Completion Date

March 21, 2023

Conditions

Healthy

Interventions

DRUG

IFN-β inhibitor treatment

PF-06823859 (IFN-β inhibitor) 100 mg/mL solution for injection

OTHER

Placebo

Placebo for PF-06823859, 0 mg/mL solution for injection

Trial Locations (2)

Peking University Third Hospital, Beijing

Peking University Third Hospital, Beijing